Biological effects of plasma rich in growth factors (PRGF) on human endometrial fibroblasts.
OBJECTIVE
To evaluate the biological outcomes of plasma rich in growth factors (PRGF) on human endometrial fibroblasts in culture.


METHODS
PRGF was obtained from three healthy donors and human endometrial fibroblasts (HEF) were isolated from endometrial specimens from five healthy women. The effects of PRGF on cell proliferation and migration, secretion of vascular endothelial growth factor (VEGF), procollagen type I and hyaluronic acid (HA) and contractility of isolated and cultured human endometrial fibroblasts (HEF) were analyzed. Statistical analysis was performed in order to compare the effects of PRGF with respect to control situation (T-test or Mann-Whitney U-test).


RESULTS
We report a significantly elevated human endometrial fibroblast proliferation and migration after treatment with PRGF. In addition, stimulation of HEF with PRGF induced an increased expression of the angiogenic factor VEGF and favored the endometrial matrix remodeling by the secretion of procollagen type I and HA and endometrial regeneration by elevating the contractility of HEF. These results were obtained for all PRGF donors and each endometrial cell line.


CONCLUSIONS
The myriad of growth factors contained in PRGF promoted HEF proliferation, migration and synthesis of paracrine molecules apart from increasing their contractility potential. These preliminary results suggest that PRGF improves the biological activity of HEF in vitro, enhancing the regulation of several cellular processes implied in endometrial regeneration. This innovative treatment deserves further investigation for its potential in "in vivo" endometrial development and especially in human embryo implantation.
Biotechnology Institute (BTI), Vitoria, Spain; Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain.
Eduardo
E
Anitua
Biotechnology Institute (BTI), Vitoria, Spain.
María
M
de la Fuente
IVI Clinic Bilbao, Leioa, Bizkaia, Spain.
Marcos
M
Ferrando
IVI Clinic Bilbao, Leioa, Bizkaia, Spain.
Fernando
F
Quintana
IVI Clinic Bilbao, Leioa, Bizkaia, Spain.
Zaloa
Z
Larreategui
IVI Clinic Bilbao, Leioa, Bizkaia, Spain; Human Reproduction Unit, Cruces Hospital, BioCruces, University of the Basque Country, Basque Country, Spain.
Roberto
R
Matorras
Biotechnology Institute (BTI), Vitoria, Spain; Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain. Electronic address: gorka.orive@bti-implant.es.
Gorka
G
Orive
D000328:Adult; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D024043:Collagen Type II / Q000378:metabolism; D004717:Endometrium / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D055815:Young Adult
D024043:Collagen Type II; D036341:Intercellular Signaling Peptides and Proteins; D042461:Vascular Endothelial Growth Factor A; D006820:Hyaluronic Acid
Endometrial fibroblasts; Endometrial regeneration; Plasma rich in growth factors (PRGF); Remodeling